TARSUS PHARMACEUTICALS, INC. Interest Expense Nonoperating
TARSUS PHARMACEUTICALS, INC. (TARS) reported Interest Expense Nonoperating of $2.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $2.16M, a 3.75% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $2.13M, a 3.84% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $2.21M, a 4.24% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $2.27M, a 7.24% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2025 was $8.94M, a 13.84% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2024 was $7.85M, a 134.58% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2023 was $3.35M, a 52.16% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2022 was $2.20M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.16M 10-Q · filed 2026-08-06 | $4.28M 10-Q · filed 2026-08-06 | $6.50M derived: sum of 3 quarters · filed 2026-08-06 | $8.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.13M 10-Q · filed 2026-05-06 | $4.34M derived: sum of 2 quarters · filed 2026-05-06 | $6.61M derived: sum of 3 quarters · filed 2026-05-06 | $8.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $4.48M derived: sum of 2 quarters · filed 2026-02-23 | $6.72M derived: sum of 3 quarters · filed 2026-08-06 | $8.94M 10-K · filed 2026-02-23 |
| 2025-09-30 | $2.27M 10-Q · filed 2025-11-04 | $4.51M derived: sum of 2 quarters · filed 2026-08-06 | $6.72M 10-Q · filed 2025-11-04 | $9.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.24M 10-Q · filed 2026-08-06 | $4.45M 10-Q · filed 2026-08-06 | $6.76M derived: sum of 3 quarters · filed 2026-08-06 | $9.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.21M 10-Q · filed 2026-05-06 | $4.53M derived: sum of 2 quarters · filed 2026-05-06 | $6.97M derived: sum of 3 quarters · filed 2026-05-06 | $9.08M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $4.76M derived: sum of 2 quarters · filed 2026-02-23 | $6.87M derived: sum of 3 quarters · filed 2026-02-23 | $7.85M 10-K · filed 2026-02-23 |
| 2024-09-30 | $2.44M 10-Q · filed 2025-11-04 | $4.55M derived: sum of 2 quarters · filed 2025-11-04 | $5.54M 10-Q · filed 2025-11-04 | $6.53M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $2.11M 10-Q · filed 2025-08-06 | $3.09M 10-Q · filed 2025-08-06 | $4.08M derived: sum of 3 quarters · filed 2026-02-23 | $4.94M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $983.00K 10-Q · filed 2025-05-01 | $1.97M derived: sum of 2 quarters · filed 2026-02-23 | $2.83M derived: sum of 3 quarters · filed 2026-02-23 | $3.65M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $989.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.85M derived: sum of 2 quarters · filed 2026-02-23 | $2.66M derived: sum of 3 quarters · filed 2026-02-23 | $3.35M 10-K · filed 2026-02-23 |
| 2023-09-30 | $858.00K 10-Q · filed 2024-11-13 | $1.67M derived: sum of 2 quarters · filed 2024-11-13 | $2.36M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $815.00K 10-Q · filed 2024-08-08 | $1.50M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $2.20M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |